In urothelial carcinoma, reduced miR-100 expression correlates with aberrant FGFR3 activation and enhanced downstream signaling, implicating the miR-100-associated non-coding RNA regulatory networks in modulating drug sensitivity and acquired resistance in FGFR-driven malignancies [304,305]. This evidence concerns the gene FGFR3 and urothelial carcinoma.